NQF

Immunohistochemistry Assay, Antibody, Epidermal Growth Factor Receptor

Product code
NQF
Device name
Immunohistochemistry Assay, Antibody, Epidermal Growth Factor Receptor
Device class
Class 3
21 CFR
21 CFR 864.1860
Medical specialty
Hematology
Marketing pathway
PMA

FDA classification definition

The epidermal growth factor receptor (EGFR) antibody/assay is a qualitative immunohistochemical antibody/assay to identify EGFR expression in normal and neoplastic tissues routinely-fixed for histological evaluation. EGFR antibody/assay specifically detects the EGFR (HER1) protein in EGFR-expressing cells. This antibody/assay is indicated as an aid in identifying colorectal cancer patients eligible for treatment with cetuximab, a monoclonal antibody drug. This will be a specialized subcategory for EGFR immunohistochemistry assays under the general heading of the regulation for all Immunohistochemistry assays.

Definition text from the FDA device classification database (U.S. federal government work, public domain).

Official FDA classification page: NQF
Classification and pathway per current FDA publications. Data from openFDA (CC0).